Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 45

1.

Diabetes mellitus induced by somatostatin analogue therapy is not permanent in acromegalic patients.

Cappellani D, Urbani C, Sardella C, Scattina I, Marconcini G, Lupi I, Manetti L, Marcocci C, Bogazzi F.

Endocrinol Diabetes Metab. 2018 Oct 5;2(1):e00033. doi: 10.1002/edm2.33. eCollection 2019 Jan.

2.

Correction to: Pegvisomant in acromegaly: an update.

Giustina A, Arnaldi G, Bogazzi F, Cannavò S, Colao A, De Marinis L, De Menis E, Degli Uberti E, Giorgino F, Grottoli S, Lania AG, Maffei P, Pivonello R, Ghigo E.

J Endocrinol Invest. 2018 Feb;41(2):267. doi: 10.1007/s40618-017-0800-1.

3.

Pegvisomant in acromegaly: an update.

Giustina A, Arnaldi G, Bogazzi F, Cannavò S, Colao A, De Marinis L, De Menis E, Degli Uberti E, Giorgino F, Grottoli S, Lania AG, Maffei P, Pivonello R, Ghigo E.

J Endocrinol Invest. 2017 Jun;40(6):577-589. doi: 10.1007/s40618-017-0614-1. Epub 2017 Feb 7. Review. Erratum in: J Endocrinol Invest. 2017 Dec 28;:.

4.

Disease activity and lifestyle influence comorbidities and cardiovascular events in patients with acromegaly.

Sardella C, Cappellani D, Urbani C, Manetti L, Marconcini G, Tomisti L, Lupi I, Rossi G, Scattina I, Lombardi M, Di Bello V, Marcocci C, Martino E, Bogazzi F.

Eur J Endocrinol. 2016 Nov;175(5):443-53. doi: 10.1530/EJE-16-0562. Epub 2016 Aug 15.

PMID:
27528501
5.

Does pegvisomant treatment expertise improve control of resistant acromegaly? The Italian ACROSTUDY experience.

Cannavo S, Bogazzi F, Colao A, De Marinis L, Maffei P, Gomez R, Graziano E, Monterubbianesi M, Grottoli S; “Italian Acrostudy Group”.

J Endocrinol Invest. 2015 Oct;38(10):1099-109. doi: 10.1007/s40618-015-0289-4. Epub 2015 Apr 28.

PMID:
25916431
6.

Use of Pegvisomant in acromegaly. An Italian Society of Endocrinology guideline.

Giustina A, Ambrosio MR, Beck Peccoz P, Bogazzi F, Cannavo' S, De Marinis L, De Menis E, Grottoli S, Pivonello R.

J Endocrinol Invest. 2014 Oct;37(10):1017-30. doi: 10.1007/s40618-014-0146-x. Epub 2014 Sep 23. No abstract available.

7.

ACROSTUDY: the Italian experience.

Grottoli S, Maffei P, Bogazzi F, Cannavò S, Colao A, Ghigo E, Gomez R, Graziano E, Monterubbianesi M, Jonsson P, De Marinis L.

Endocrine. 2015 Feb;48(1):334-41. doi: 10.1007/s12020-014-0393-9. Epub 2014 Aug 23.

PMID:
25150035
8.

A novel germline mutation in the aryl hydrocarbon receptor-interacting protein (AIP) gene in an Italian family with gigantism.

Urbani C, Russo D, Raggi F, Lombardi M, Sardella C, Scattina I, Lupi I, Manetti L, Tomisti L, Marcocci C, Martino E, Bogazzi F.

J Endocrinol Invest. 2014 Oct;37(10):949-55. doi: 10.1007/s40618-014-0123-4. Epub 2014 Jul 5.

PMID:
24996936
9.

The beneficial effect of acromegaly control on blood pressure values in normotensive patients.

Sardella C, Urbani C, Lombardi M, Nuzzo A, Manetti L, Lupi I, Rossi G, Del Sarto S, Scattina I, Di Bello V, Martino E, Bogazzi F.

Clin Endocrinol (Oxf). 2014 Oct;81(4):573-81. doi: 10.1111/cen.12455. Epub 2014 May 5.

PMID:
24661019
10.

Role of UGT1A1 and ADH gene polymorphisms in pegvisomant-induced liver toxicity in acromegalic patients.

Filopanti M, Barbieri AM, Mantovani G, Corbetta S, Gasco V, Ragonese M, Martini C, Bogazzi F, Colao A, Ferone D, Peri A, Pigliaru F, Angeletti G, Arosio M, Beck-Peccoz P, Lania AG, Spada A.

Eur J Endocrinol. 2013 Dec 21;170(2):247-54. doi: 10.1530/EJE-13-0657. Print 2014 Feb.

PMID:
24217933
11.

Growth hormone is necessary for the p53-mediated, obesity-induced insulin resistance in male C57BL/6J x CBA mice.

Bogazzi F, Raggi F, Russo D, Bohlooly-Y M, Sardella C, Urbani C, Lombardi M, Manetti L, Lupi I, Tornell J, Martino E.

Endocrinology. 2013 Nov;154(11):4226-36. doi: 10.1210/en.2013-1220. Epub 2013 Aug 2.

PMID:
23913444
12.

Comparison of the effects of primary somatostatin analogue therapy and pituitary adenomectomy on survival in patients with acromegaly: a retrospective cohort study.

Bogazzi F, Colao A, Rossi G, Lombardi M, Urbani C, Sardella C, Iannelli A, Scattina I, Manetti L, Del Sarto S, Pivonello R, Grasso LF, Lupi I, Auriemma RS, Lombardi G, Martino E.

Eur J Endocrinol. 2013 Aug 28;169(3):367-76. doi: 10.1530/EJE-13-0166. Print 2013 Sep.

PMID:
23828855
13.

Effects of medical therapies for acromegaly on glucose metabolism.

Urbani C, Sardella C, Calevro A, Rossi G, Scattina I, Lombardi M, Lupi I, Manetti L, Martino E, Bogazzi F.

Eur J Endocrinol. 2013 Jun 7;169(1):99-108. doi: 10.1530/EJE-13-0032. Print 2013 Jul.

PMID:
23660641
14.

Serum factors associated with precancerous colonic lesions in acromegaly.

Lombardi M, Scattina I, Sardella C, Urbani C, Marciano E, Signori S, Ruocco L, Pellegrini G, Martino E, Bogazzi F.

J Endocrinol Invest. 2013 Sep;36(8):545-9. doi: 10.3275/8812. Epub 2013 Jan 14.

PMID:
23324452
15.

Growth hormone receptor variants and response to pegvisomant in monotherapy or in combination with somatostatin analogs in acromegalic patients: a multicenter study.

Filopanti M, Olgiati L, Mantovani G, Corbetta S, Arosio M, Gasco V, De Marinis L, Martini C, Bogazzi F, Cannavò S, Colao A, Ferone D, Arnaldi G, Pigliaru F, Peri A, Angeletti G, Jaffrain-Rea ML, Lania AG, Spada A.

J Clin Endocrinol Metab. 2012 Feb;97(2):E165-72. doi: 10.1210/jc.2011-1769. Epub 2011 Dec 7.

PMID:
22162472
16.

Cardiac extrinsic apoptotic pathway is silent in young but activated in elder mice overexpressing bovine GH: interplay with the intrinsic pathway.

Bogazzi F, Russo D, Raggi F, Bohlooly-Y M, Tornell J, Sardella C, Lombardi M, Urbani C, Manetti L, Brogioni S, Martino E.

J Endocrinol. 2011 Aug;210(2):231-8. doi: 10.1530/JOE-10-0402. Epub 2011 May 12.

PMID:
21565853
17.

Assessment of the awareness and management of sleep apnea syndrome in acromegaly. The COM.E.TA (Comorbidities Evaluation and Treatment in Acromegaly) Italian Study Group.

De Menis E, Giustina A, Colao A, Degli Uberti E, Ghigo E, Minuto F, Bogazzi F, Drigo R, Cattaneo A, Aimaretti G; COM.E.T.A. Italian Study Group.

J Endocrinol Invest. 2011 Jan;34(1):60-4. Erratum in: J Endocrinol Invest. 2011 Feb;34(2):169.

PMID:
21406941
18.

Impact of different cut-off limits of peak GH after GHRH-arginine stimulatory test, single IGF1 measurement, or their combination in identifying adult patients with GH deficiency.

Bogazzi F, Manetti L, Lombardi M, Giovannetti C, Raffaelli V, Urbani C, Scattina I, Pepe P, Iannelli A, Martino E, Rossi G.

Eur J Endocrinol. 2011 May;164(5):685-93. doi: 10.1530/EJE-10-1068. Epub 2011 Feb 9.

PMID:
21307143
19.

Effects of high-dose octreotide LAR on glucose metabolism in patients with acromegaly inadequately controlled by conventional somatostatin analog therapy.

Mazziotti G, Porcelli T, Bogazzi F, Bugari G, Cannavò S, Colao A, Cozzi R, De Marinis L, degli Uberti E, Grottoli S, Minuto F, Montini M, Spinello M, Giustina A.

Eur J Endocrinol. 2011 Mar;164(3):341-7. doi: 10.1530/EJE-10-0811. Epub 2011 Jan 6.

PMID:
21212103
20.

Somatostatin analogues do not affect calcium metabolism in patients with acromegaly and primary hyperparathyroidism [corrected] due to MEN 1-like syndrome.

Bogazzi F, Lombardi M, Russo D, Sardella C, Raggi F, Brogioni S, Cetani F, Ceccarelli C, Mariani G, Basolo F, Martino E.

Horm Metab Res. 2011 Feb;43(2):126-9. doi: 10.1055/s-0030-1267915. Epub 2010 Oct 22. Erratum in: Horm Metab Res. 2011 Feb;43(2). 10.1055/s-0030-1268482.

PMID:
20972944

Supplemental Content

Loading ...
Support Center